CWC
NVAX icon

Carolinas Wealth Consulting’s Novavax NVAX Stock Holding History

Carolinas Wealth Consulting’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-165
Closed -$30K – 986
2021
Q1 		$30K Hold
165
– – 0.01% 445
2020
Q4 		$18K Sell
165
-5
-3% -$531 ﹤0.01% 497
2020
Q3 		$18K Buy
+170
New +$20.7K 0.01% 405

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carolinas Wealth Consulting's NVAX Position: Q2 2021 in Review

Carolinas Wealth Consulting sold out of Novavax (NVAX) in Q2 2021, closing a stake of 165 shares — an estimated $30K sold.

Carolinas Wealth Consulting first reported a position in NVAX in Q3 2020 and held it in 3 quarters. The position peaked at $30K in Q1 2021. 407 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Carolinas Wealth Consulting reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 165 Novavax shares in Q2 2021, an estimated $30K.
  • Carolinas Wealth Consulting first reported a position in Novavax in Q3 2020 and held it in 3 quarters.
  • Carolinas Wealth Consulting's Novavax position peaked at $30K in Q1 2021.
  • 407 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2021, filed 17 Aug 2021.